HT

Henri Termeer

Europe, Noord-Brabant, The Netherlands, Tilburg

Description

Henri Termeer has served as a director of AVEO since April 2011 and is Chairman of the Board. He served as chairman, president and chief exe...

Investor Profile

Henri Termeer has made 5 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (40%)
  • Series A (40%)
  • Series E (20%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Biopharma
  • Health Care
  • Health Diagnostics
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Henri Termeer frequently co-invest with?

HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 1
Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 1
Nextech Invest
Europe, Zurich, Switzerland, Zürich
Co-Investments: 1
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 1
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 2
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 1
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 1
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 3
Celgene
North America, New Jersey, United States, Summit
Co-Investments: 2
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 2

What are some of recent deals done by Henri Termeer?

Arrakis Therapeutics

Waltham, Massachusetts, United States

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series BApr 18, 2019
Amount Raised: $75,000,000
Arrakis Therapeutics

Waltham, Massachusetts, United States

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series AFeb 27, 2017
Amount Raised: $38,000,000
Aura Biosciences

Cambridge, Massachusetts, United States

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

BiotechnologyHealth CarePharmaceutical
Series BMar 5, 2015
Amount Raised: $21,000,000
Lysosomal Therapeutics

Cambridge, Massachusetts, United States

Lysosomal Therapeutics deliver cures for neurodegenerative diseases.

BiotechnologyHealth CareTherapeutics
Series AFeb 3, 2015
Amount Raised: $20,000,000
NanoString Technologies

Seattle, Washington, United States

NanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.

BiotechnologyHealth DiagnosticsMedical
Series EDec 3, 2012
Amount Raised: $15,300,000